News

CDRD and Zucara are working in partnership to develop unique compounds that will lead to a new safe and effective long-term therapeutic approach as the first once-daily therapeutic

Eravacycline is a novel antibiotic candidate with potent activity against multidrug-resistant (MDR) pathogens, including carbapenem-resistant enterobacteriaceae (CRE), Acinetobacter baumannii, and colistin-resistant bacteria carrying the mcr-1 gene, that is

Following the enrollment of the initial nine patients in the study, the company suspended dosing of patients after observing increases in alanine aminotransferase (ALT) levels that crossed a

Prurigo nodularis (PN), a severely pruritic dermatological condition characterized by itchy skin papules and nodules, has significant impact on quality of life and has no approved therapies. Trevi

The company, located in the Pharma Valley of Nanjing's High-Tech Zone which can be easily accessed within one hour from Shanghai by high-speed train, announced the fundraising today.

The site will house VBL's local biological drugs manufacturing facility, as the company plans ahead for potential commercialization of VB-111. The site design enables modular expansion of the

CAD is an autoimmune hemolytic anemia in which autoantibodies target and destroy red blood cells, resulting in anemia, fatigue and potentially fatal thrombosis. TNT009 selectively inhibits C1s, a

QIDP status offers for an additional five years of market exclusivity, if approved. Fast Track status provides for more frequent interactions with the FDA review team and a

The definitive pharmacokinetic study and the comparative pain study for the Makena (hydroxyprogesterone caproate injection) subcutaneous auto-injector program (Makena SQ) have been initiated with the first patient dosed. The